Napier Park Global Capital
Acquisition in 2022
Napier Park Global Capital is an independent alternative asset management firm founded in 2013 and located in New York City. The firm specializes in alternative credit and structured equity investments, managing approximately $6.7 billion across a diversified range of products. Its offerings include hedge funds, bespoke client separate accounts, private investments, and collateralized loan obligations. Napier Park serves large, sophisticated institutional investors and focuses on providing capital solutions through primary, secondary, and special situations financing. The firm targets various sectors, including healthcare, commercial products, software, restaurants, manufacturing, and space technology, aiming to deliver equity, debt, or hybrid capital for growth, acquisition, or recapitalization opportunities.
QualityMetric
Debt Financing in 2020
QualityMetric is a leader in the development of patient-reported outcome (PRO) and clinical outcomes assessment (COA) products, focusing on the healthcare and life sciences sectors. With over thirty years of experience, the company specializes in standardizing functional health status assessments through scientifically validated surveys that address both general health and specific diseases. QualityMetric employs proprietary methodologies to capture, benchmark, and interpret health outcomes data, providing comprehensive and tailored measurement solutions. Their offerings include a wide range of surveys, advanced analytics, and expert consulting services, aimed at enhancing the understanding of patient health and well-being. By collaborating with leading healthcare and life science companies, QualityMetric plays a vital role in clinical trials and patient surveillance, ultimately contributing to improved healthcare outcomes.
THL Credit
Acquisition in 2019
THL Credit, Inc. is a business development company focused on direct and fund of fund investments primarily in the debt and equity securities of middle market companies. The firm aims to engage in various financial transactions, including growth, acquisition, and recapitalization, while avoiding start-ups and operationally distressed companies. Its investment strategy includes unsecured subordinated or mezzanine debt, second lien secured debt, and may also involve equity components like warrants and preferred stock. THL Credit typically invests between $10 million and $25 million per transaction, targeting companies with annual revenues between $25 million and $500 million and EBITDA ranging from $5 million to $25 million. The firm has a diverse investment focus, including sectors such as outsourced business services, healthcare, financials, retailing, media, and consumer discretionary. With a national presence and offices in several major cities, THL Credit is positioned as a significant player in the alternative credit investment space, managing approximately $9.5 billion in assets.
Sciens Building Solutions
Venture Round in 2018
Sciens Building Solutions specializes in fire detection and security services, focusing on the design, installation, and maintenance of fire detection and clean agent fire suppression systems. The company serves a diverse range of sectors, including hospitality, transportation, healthcare, retail, and government. By offering comprehensive integrated systems for data communication, emergency responder communication, fire safety, life safety, and security, Sciens Building Solutions ensures that its clients' facilities remain safe, secure, and compliant with industry standards.
NewStar Financial
Acquisition in 2017
NewStar Financial is a specialized commercial finance company that addresses the complex financing needs of middle market companies and private investors. Founded in 2004 and based in Massachusetts, the firm focuses on providing senior secured debt financing options to mid-sized businesses for various purposes, including working capital, growth strategies, acquisitions, recapitalizations, and equipment purchases. NewStar originates loans and leases through experienced teams of senior bankers and marketing officers who are organized by key industry and market segments, ensuring tailored financial solutions for its clients.
Wheels Up Partners
Venture Round in 2014
Wheels Up is a membership-based private aviation company that specializes in on-demand flight services in the United States. By leveraging data and technology, it connects consumers with safety-vetted private aircraft, offering both programmatic and charter options. The company aims to reduce the upfront costs associated with private flying while providing flexibility, service, and safety to its members. Through its mobile app, users can easily book flights, manage accounts, and access ride-share opportunities. Additionally, members participate in the Wheels Down program, which enhances their travel experiences. Wheels Up operates a diverse fleet, utilizing owned, leased, and chartered aircraft to provide a wide range of global travel alternatives.
EUSA Pharma
Venture Round in 2007
EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.